吸入沙美特罗替卡松联合口服孟鲁司特治疗支气管哮喘的临床观察

Clinical Observation of Salmeterol and Fluticasone Propionate Combined with Montelukast for Bronchial Asthma

目的探讨吸入沙美特罗替卡松联合口服孟鲁司特治疗支气管哮喘的临床疗效,减少患者哮喘急性发作。方法选取符合标准的患者80例,随机分为观察组和对照组各40例,对照组给予口服孟鲁司特,观察组在此基础上加用沙美特罗替卡松粉吸入剂,比较二者临床发作及肺功能改善等情况。结果治疗3个疗程后,观察组患者临床有效率95.00%,对照组为82.50%,二者差异有统计学意义(χ2=4.114,P=0.043)。治疗前,两组患者肺功能各项指标及哮喘控制测试表(ACT)评分比较,差异无统计学意义(P>0.05);治疗3个疗程后,两组患者肺功能各项指标水平及ACT评分较治疗前均提高(P<0.05),但是观察组患者改善幅度更大(P<0.05)。结论吸入沙美特罗替卡松联合口服孟鲁司特治疗支气管哮喘,兼顾改善症状和减轻炎症,具有较好的临床疗效;吸入疗法具有给药剂量小、作用迅速、吸收完全及不良反应少等特点,是治疗支气管哮喘的理想途径。

Objective To discuss the clinical effects of Salmeterol and fluticasone propionate combined with montelukast for bronchial asthma, reduce acute episode of bronchial asthma. Methods 80 patients were divided randomly into observation group （40 eases） and control group （40 cases） . The observation group was treated with salmeterol and fluticasone propionate combined with montelukast, and the control group was treated with montelukast. Then two groups of clinical seizures and lung function were compared. Results 3 courses later, the effective rate was 95% in the observation group, and 82.5% in the control group （X^2=4.114, P=0.043）; The indicators for lung function and asthma control test （ACT） of all patients improved than before （P〈0.05）, However, improvement was greater in the observation group. Conclusion Salmeterol and fluticasone propionate combined with montelukast for bronchial asthma can obtain a better effect for treatment of bronchial asthma, with the advantage of improved symptoms, reduced inflammation, small dosage, fast-acting, completely absorbed and fewer adverse reactions.